Establishment of primary mouse lung adenocarcinoma cell culture

Oncology Letters

Volumn 2, Issue 4, 2011, Pages 629-632

  Luo, Shuli ^a   Sun, Mei ^a   Jiang, Rui ^b   Wang, Guan ^a   Zhang, Xinyi ^a  

^a THE SECOND HOSPITAL OF JILIN UNIVERSITY   (China)

^b CHINA JAPAN UNION HOSPITAL OF JILIN UNIVERSITY   (China)

Author keywords

Epithelial; Lung cancer; Primary culture; Tumourigenicity

Indexed keywords

ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CARCINOGENICITY; CONTROLLED STUDY; CULTURE MEDIUM; DNA REPAIR; ELECTRON MICROSCOPY; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG ALVEOLUS EPITHELIUM; MOUSE; NONHUMAN; TECHNIQUE;

EID: 79958020934     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2011.301     Document Type: Article

References (20)

1. Stewart BW and Kleihues P (eds): World Cancer Report. IARC Press, Lyon, p182, 2003.
2. Butnor KJ and Beasley MB: Resolving dilemmas in lung cancer staging and histologic typing. Arch Pathol Lab Med 131: 1014-1015, 2007.
3. Mulshine JL and Henschke CI: Prospects for lung-cancer screening. Lancet 355: 592-593, 2000.
4. Wright GS and Gruidl ME: Early detection and prevention of lung cancer. Curr Opin Oncol 12: 143-148, 2000.
5. Zhang X, Miao X, Liang G, et al: Polymorphisms in DNA base excision repair genes ADPRT and XRCC1 and risk of lung cancer. Cancer Res 65: 722-726, 2005.
6. Shao M, Ma H, Wang Y, et al: Polymorphisms in excision repair cross-complementing group 4 (ERCC4) and susceptibility to primary lung cancer in a Chinese Han population. Lung Cancer 60: 332-339, 2008.
7. Bartek J, Lukas J and Bartkova J: DNA damage response as an anti-cancer barrier: damage threshold and the concept of 'conditional haploinsufficiency'. Cell Cycle 6: 2344-2347, 2007.
8. Tong WM, Cortes U, Hande MP, et al: Synergistic role of Ku80 and poly(ADP-ribose) polymerase in suppressing chromosomal aberrations and liver cancer formation. Cancer Res 62: 6990-6996, 2002.
9. Tong WM, Yang YG, Cao WH, et al: Poly(ADP-ribose) polymerase-1 plays a role in suppressing mammary tumourigenesis in mice. Oncogene 26: 3857-3867, 2007.
10. Tong W-M, Hande MP, Lansdorp PM and Wang ZQ: DNA-strand break-sensing molecule PARP cooperates with p53 in telomere function, chromosomal stability and tumour suppression. Mol Cell Biol 21: 4046-4054, 2001
11. Wang CG, Sun M, Zhao XJ and Zhang XY: Effect of STAT3 siRNA-induced inhibition of STAT3 gene expression on the growth and apoptosis of Lewis lung cancer cells. Chin J Clin Oncol 3: 392-399, 2006.
12. Wang CG, Wang RY, Sun M, et al: In vivo antitumour effect of siRNA against STAT3 on transplanted Lewis lung cancer in mice. Chem Res Chin Univ 24: 322-329, 2008.
13. Tong WM, Ohgaki H, Huang H, Granier C, Kleihues P and Wang ZQ: Null mutation of DNA strand break-binding molecule poly(ADP-ribose) polymerase causes medulloblastomas in p53(-/-) mice. Am J Pathol 162: 343-352, 2003.
14. Yang S, Su J, Cao J, Zhang P, Lu J, and Xie W: Establishment of a novel Chinese human lung adenocarcinoma cell line CPA-Yang1 which produces highly bone metastases in immunodeficient mice. Zhongguo Fei Ai Za Zhi 12: 753-759, 2009.
15. Yaghi A, Zaman A and Dolovich M: Primary human bronchial epithelial cells grown from explants. J Vis Exp 26: pii: 1789, doi: 10.3791/1789.
16. Kalinina T, Gungor C, Thieltges S, et al: Establishment and characterization of a new human pancreatic adenocarcinoma cell line with high metastatic potential to the lung. BMC Cancer 10: 295, 2010.
17. Higashiyama M, Oda K, Okami J, et al: Prediction of chemotherapeutic effect on postoperative recurrence by in vitro anticancer drug sensitivity testing in non-small cell lung cancer patients. Lung Cancer 68: 472-477, 2010.
18. Camps C, Sirera R, Iranzo V, Taron M and Rosell R: Gene expression and polymorphisms of DNA repair enzymes: cancer susceptibility and response to chemotherapy. Clin Lung Cancer 8: 369-375, 2007.
19. Hardwicke MA, Oleykowski CA, Plant R, et al: GSK1070916, a potent Aurora B/C kinase inhibitor with broad antitumour activity in tissue culture cells and human tumour xenograft models. Mol Cancer Ther 8: 1808-1817, 2009.
20. Powell C, Mikropoulos C, Kaye SB, et al: Pre-clinical and clinical evaluation of PARP inhibitors as tumour-specific radiosensitisers. Cancer Treat Rev 36: 566-575, 2010.